Home » Stocks » RGEN

Repligen Corporation (RGEN)

Stock Price: $235.28 USD 8.90 (3.93%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
After-hours: $237.85 +2.57 (1.09%) Jul 28, 7:51 PM
Market Cap 12.92B
Revenue (ttm) 508.51M
Net Income (ttm) 99.93M
Shares Out 54.93M
EPS (ttm) 1.46
PE Ratio 161.59
Forward PE 161.29
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $235.28
Previous Close $226.38
Change ($) 8.90
Change (%) 3.93%
Day's Open 226.26
Day's Range 224.56 - 240.49
Day's Volume 774,133
52-Week Range 137.15 - 240.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. The company also raises its guidance for 2021.

17 hours ago - Zacks Investment Research

When in search of value opportunities, investors could be interested in the following three stocks, as they represent equities in companies with high profitability and robust financial conditions. These...

Other stocks mentioned: KEYS, SEDG
1 day ago - GuruFocus

Repligen (RGEN) delivered earnings and revenue surprises of 49.06% and 12.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 day ago - Zacks Investment Research

Shares of Repligen (NASDAQ:RGEN) moved higher by 0.0% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 88.10% over the past year to $0.79, which ...

1 day ago - Benzinga

WALTHAM, Mass., July 27, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its sec...

1 day ago - GlobeNewsWire

Repligen (NASDAQ:RGEN) announces its next round of earnings this Tuesday, July 27. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.

2 days ago - Benzinga

Don't overthink it -- buy companies with excellent financials and a long runway for growth.

Other stocks mentioned: RMD, VEEV
6 days ago - The Motley Fool

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

Webcast and Conference Call to Be Held Tuesday, July 27, 2021 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Tuesday, July 27, 2021 at 8:30 a.m. EDT

2 weeks ago - GlobeNewsWire

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

Other stocks mentioned: AMGN, BIIB, BNTX, MRNA, NTLA, REGN
3 weeks ago - Zacks Investment Research

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: IMMR, NKE, ROCK, SMTC
3 weeks ago - Zacks Investment Research

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified The New York Times Company among others.

Other stocks mentioned: NYT, MA, W, WFC
4 weeks ago - Forbes

Repligen Corporation (NASDAQ: RGEN) has agreed to acquire France-based Polymem S.A., a provider of hollow fiber membranes and modules.

1 month ago - Benzinga

WALTHAM, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an ...

1 month ago - GlobeNewsWire

RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.

Other stocks mentioned: RAPT, REGN, SNY
1 month ago - Zacks Investment Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.

Other stocks mentioned: NVS, CVAC, REGN
2 months ago - Zacks Investment Research

WALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtuall...

2 months ago - GlobeNewsWire

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

Other stocks mentioned: OVID, REGN
2 months ago - Zacks Investment Research

Repligen (RGEN) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

2 months ago - Zacks Investment Research

The current system has created a tremendous wealth gap in America. Which is why I've decided to tackle it head on.

Other stocks mentioned: VIPS
2 months ago - InvestorPlace

Herbalife (HLF), DaVita (DVA), Apple (AAPL), Century Communities (CCS) & Repligen (RGEN) are the top stocks that flaunt attractive earnings growth at present.

Other stocks mentioned: AAPL, CCS, DVA, HLF
2 months ago - Zacks Investment Research

Repligen (RGEN) reports encouraging first-quarter results with sales and earnings beating estimates. The company also raises its guidance for 2021.

2 months ago - Zacks Investment Research

Repligen (RGEN) delivered earnings and revenue surprises of 58.14% and 22.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Repligen (NASDAQ:RGEN) moved higher by 7.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 112.50% over the past year to $0.68, which be...

2 months ago - Benzinga

WALTHAM, Mass., May 04, 2021 (GLOBE NEWSWIRE) --  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fir...

2 months ago - GlobeNewsWire

Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT

3 months ago - GlobeNewsWire

These names are major disruptors in their respective industries. Could one of them be the next Tesla?

Other stocks mentioned: APPS, ETSY, LOVE, NIO, OKTA, TRUP
3 months ago - InvestorPlace

Financial media can often divert your attention away from the best investments.

Other stocks mentioned: ALGN, DXCM
3 months ago - The Motley Fool

These companies are set to keep riding upward thanks to long-term secular trends.

Other stocks mentioned: APPS, PYPL
4 months ago - The Motley Fool

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Repligen (RGEN).

4 months ago - Zacks Investment Research

WALTHAM, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtua...

4 months ago - GlobeNewsWire

WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtua...

4 months ago - GlobeNewsWire

Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations.

5 months ago - Zacks Investment Research

Repligen (RGEN) beat estimates for both earnings and revenues in the fourth quarter of 2020.

5 months ago - Zacks Investment Research

Shares of Repligen (NASDAQ:RGEN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 160.00% year over year to $0.52, which beat the estimate of $0.31.

5 months ago - Benzinga

Repligen easily beat earnings and revenue views and guided high for the current fiscal year. RGEN stock jumped Wednesday.

5 months ago - Investors Business Daily

WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fou...

5 months ago - GlobeNewsWire

WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...

5 months ago - GlobeNewsWire

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

In the latest trading session, Repligen (RGEN) closed at $223.39, marking a +1.95% move from the previous day.

5 months ago - Zacks Investment Research

Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company...

5 months ago - GlobeNewsWire

On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.

5 months ago - Zacks Investment Research

WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Protei...

5 months ago - GlobeNewsWire

Repligen (RGEN) closed the most recent trading day at $222.06, moving +1.9% from the previous trading session.

5 months ago - Zacks Investment Research

When it comes to coronavirus vaccines, think of Repligen as the man behind the curtain and RGEN stock as a tools powerhouse. Shares broke out of a cup base in January and hover in a buy zone.

5 months ago - Investors Business Daily

The tailwinds behind the company's gains aren't going anywhere.

6 months ago - The Motley Fool

WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...

6 months ago - GlobeNewsWire

The bioprocessing technology company gained momentum during the coronavirus pandemic.

6 months ago - The Motley Fool

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput... [Read more...]

Industry
Medical Instruments & Supplies
Founded
1981
CEO
Anthony Hunt
Employees
1,128
Stock Exchange
NASDAQ
Ticker Symbol
RGEN
Full Company Profile

Financial Performance

In 2020, Repligen's revenue was $366.26 million, an increase of 35.53% compared to the previous year's $270.25 million. Earnings were $59.93 million, an increase of 179.88%.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Repligen stock is "Strong Buy." The 12-month stock price forecast is 238.86, which is an increase of 1.52% from the latest price.

Price Target
$238.86
(1.52% upside)
Analyst Consensus: Strong Buy